Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates
Iovance Biotherapeutics reported its second quarter 2021 financial results, highlighting advances in TIL therapy for cancer. The company has a cash position of $708.7 million as of June 30, sufficient to fund operations through 2023. Key clinical data was presented, showing an 86% overall response rate for lifileucel in combination with pembrolizumab for anti-PD-1 naïve melanoma. However, the net loss for Q2 was $81.4 million, an increase from $63 million in Q2 2020, with R&D expenses rising to $62.1 million.
- Cash position of $708.7 million expected to fund operations into 2023.
- 86% overall response rate for lifileucel in anti-PD-1 naïve melanoma.
- 90% manufacturing success rate for TIL products.
- Net loss of $81.4 million in Q2 2021, compared to $63 million in Q2 2020.
- R&D expenses increased by $12.8 million compared to Q2 2020.
Expanding Leadership for TIL Cell Therapy in Solid Tumors
SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.
Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “During the first half of 2021 we advanced our TIL pipeline and presented clinical data across multiple solid tumor indications and treatment settings, including single-agent TIL in metastatic non-small cell lung cancer and melanoma, as well as initial clinical data for TIL in combination with pembrolizumab in early line melanoma. Our top priority remains our ongoing work to address FDA feedback regarding the potency assays for lifileucel to support our planned BLA submission. We are increasingly confident in the broad potential for TIL as the next class of paradigm-shifting therapy for cancer patients with significant unmet need.”
Second Quarter 2021 Highlights and Recent Corporate Updates
Regulatory
- Potency assays for lifileucel: Following FDA feedback regarding the potency assays for lifileucel, Iovance will continue ongoing work developing and validating its potency assays and plans to submit additional assay data and anticipates meeting with the FDA before the end of 2021. The company's biologics license application (BLA) submission for lifileucel is now expected to occur during the first half of 2022. Resolution of the potency assay for lifileucel in melanoma is also a key step towards our regulatory plans in other indications.
Clinical
- TIL therapy in melanoma:
- Metastatic melanoma: follow up data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting. As of the April 2021 data cutoff for the presentation, the overall response rate (ORR) was
36.4% (4.5% complete response rate and31.8% partial response rate) and median duration of response (DOR) was not reached at 33.1 months of median study follow up as assessed by investigators (n=66). Detailed Cohort 2 data were also published in a manuscript in the Journal of Clinical Oncology, an ASCO journal.
- Metastatic melanoma: follow up data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting. As of the April 2021 data cutoff for the presentation, the overall response rate (ORR) was
- Anti-PD-1 naïve melanoma: initial clinical data for lifileucel in combination with pembrolizumab were presented in a poster at ASCO 2021. The ORR was
86% and the complete response rate was43% at a median follow up of 8.2 months in anti-PD-1 naïve melanoma patients in Cohort 1A in the IOV-COM-202 basket study (n=7).
- TIL therapy in non-small cell lung cancer (NSCLC):
- LN-145 clinical data in metastatic NSCLC (mNSCLC): clinical data for LN-145 showed a
21.4% ORR and64.3% disease control rate in mNSCLC patients from Cohort 3B in the IOV-COM-202 study (n=28), including two responders with PD-L1 negative tumors. All Cohort 3B patients had received one or more prior systemic therapies, including anti-PD-1 therapy, and all responders also received prior chemotherapy. Detailed results are anticipated at a medical meeting in 2021. - LN-145 in second-line mNSCLC: the first patient was dosed and more than 15 U.S. clinical sites have been activated in the registration-supporting IOV-LUN-202 study of LN-145 in patients with mNSCLC.
- LN-145 clinical data in metastatic NSCLC (mNSCLC): clinical data for LN-145 showed a
Research
- Iovance is committed to advancing the next generation of TIL and related therapies and technologies. Late preclinical programs in IND-enabling studies include a novel IL-2 analog (IOV-3001) as well as a genetically modified TIL (IOV-4001). IOV-4001 leverages TALEN technology licensed from Cellectis S.A. to genetically knock out PD-1 in TIL cells.
Manufacturing
- TIL manufacturing success: to date, nearly 500 patients have been dosed with Iovance TIL products with more than a 90 percent manufacturing success rate.
- Iovance Cell Therapy Center (iCTC): the investigational new drug (IND) application amendment has been cleared and clinical manufacturing of TIL is expected to commence at the iCTC in the near future. Commercial manufacturing remains on track to commence with a potential regulatory approval.
Corporate
- Cash position of
$708.7 million on June 30, 2021 is expected to be sufficient well into 2023. - A strong organization of nearly 270 employees with an average of more than 3.5 years of cell therapy experience is in place to advance research, development, manufacturing, and commercial launch preparations.
- Iovance continues to expand its intellectual property portfolio and currently owns more than 25 granted or allowed U.S. and international patents for compositions and methods of treatment in a broad range of cancers relating to the Gen 2 manufacturing process. Iovance’s Gen 2 patent rights are expected to provide exclusivity through 2038. Iovance’s portfolio also includes patent applications and granted patents directed towards Gen 3 manufacturing, selected TIL products, stable and transient genetic TIL modifications, tumor digest and fragment compositions and methods (including cryopreservation), and combinations of checkpoint inhibitors and TIL products.
Second Quarter and First Half 2021 Financial Results
Iovance held
Jean-Marc Bellemin, Chief Financial Officer, stated, “Our balance sheet remains strong to advance our operating plan, including launch preparations and pipeline development, with no immediate need to raise additional capital.”
Net loss for the second quarter ended June 30, 2021, was
Research and development expenses were
The increase in research and development expenses in the second quarter 2021 over the prior year period was primarily attributable to an increase in costs associated with growth of the internal research and development team and increases in manufacturing and iCTC facility related costs. The increase in research and development expenses in the first half of 2021 over the prior year period was primarily attributable to growth of the internal research and development team, an increase in iCTC facility related costs, which were partially offset by lower manufacturing and clinical costs following the completion of enrollment in the pivotal cohorts for melanoma and cervical cancer.
General and administrative expenses were
The increases in general and administrative expenses in the second quarter and first half of 2021 compared to the prior year periods were primarily attributable to growth of the internal general and administrative team and higher stock-based compensation expenses.
Webcast and Conference Call
Iovance will host a conference call today at 4:30 p.m. ET to discuss the second quarter 2021 financial results and corporate updates. The conference call dial-in numbers are 1-(844) 646-4465 (domestic) or 1-(615) 247-0257 (international) and the access code is 1489438. The live webcast can be accessed in the Investors section of the company’s website at http://www.iovance.com. The archived webcast will be available for a year in the Investors section at www.iovance.com.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the new version of the protocol which further defines the patient population to include more advanced patients in our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.
| IOVANCE BIOTHERAPEUTICS, INC. | |||||
| Selected Condensed Consolidated Balance Sheets | |||||
| (in thousands) | |||||
| June 30, | December 31, | ||||
| 2021 | 2020 | ||||
| (Unaudited) | |||||
| Cash, cash equivalents, and investments | $ | 702,656 | $ | 629,437 | |
| Restricted cash | $ | 6,084 | $ | 5,525 | |
| Total assets | $ | 852,790 | $ | 768,458 | |
| Stockholders' equity | $ | 744,413 | $ | 656,498 | |
| IOVANCE BIOTHERAPEUTICS, INC. | |||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||
| (unaudited, in thousands, except per share information) | |||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||
| Revenues | $ | - | $ | - | $ | - | $ | - | |||||
| Costs and expenses* | |||||||||||||
| Research and development | 62,119 | 49,274 | 118,068 | 106,226 | |||||||||
| General and administrative | 19,307 | 14,353 | 38,928 | 28,211 | |||||||||
| Total costs and expenses | 81,426 | 63,627 | 156,996 | 134,437 | |||||||||
| Loss from operations | (81,426 | ) | (63,627 | ) | (156,996 | ) | (134,437 | ) | |||||
| Other income | |||||||||||||
| Interest income, net | 75 | 609 | 196 | 1,824 | |||||||||
| Net Loss | $ | (81,351 | ) | $ | (63,018 | ) | $ | (156,800 | ) | $ | (132,613 | ) | |
| Net Loss Per Share of Common Stock, Basic and Diluted | $ | (0.53 | ) | $ | (0.47 | ) | $ | (1.04 | ) | $ | (1.02 | ) | |
| Weighted-Average Shares of Common Stock Outstanding, Basic and Diluted | 153,751 | 133,162 | 150,571 | 129,848 | |||||||||
| * Includes stock-based compensation as follows | |||||||||||||
| Research and development | $ | 8,585 | $ | 5,465 | $ | 17,787 | $ | 9,783 | |||||
| General and administrative | 5,829 | 5,072 | 13,568 | 10,166 | |||||||||
| $ | 14,414 | $ | 10,537 | $ | 31,355 | $ | 19,949 | ||||||
CONTACTS
Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Vice President, Investor Relations & Public Relations
650-260-7120 ext. 264
Sara.Pellegrino@iovance.com
Solebury Trout:
Zara Lockshin
646.378.2960
zlockshin@soleburytrout.com
FAQ
What were the financial results for Iovance Biotherapeutics in Q2 2021?
What is the overall response rate for Iovance's lifileucel in melanoma?
When does Iovance plan to submit its BLA for lifileucel?
What is Iovance's cash position as of June 30, 2021?
How much did Iovance spend on R&D in Q2 2021?
